BioSpace News Archive

Rapid Micro Biosystems, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2022.

AVROBIO, Inc today announced that members of its senior management team are scheduled to participate in a panel titled “Orphan Neuro Corporate Panel” at Cowen’s 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 10:30 AM ET.

BridgeBio Pharma, Inc. today announced that members of its management team will host an investor call on Monday, March 6 at 7:30 am ET to discuss Phase 2 Cohort 5 data from its PROPEL2 clinical trial of the investigational therapy infigratinib in children with achondroplasia.

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) is pleased to announce that it has engaged Catalent (‘Catalent’) to develop and manufacture a cGMP-grade psilocybin drug product for: (1) use in Incannex’s proprietary psilocybin-assisted psychotherapy drug development program and (2), potential wider commercial use.

Biomerica, Inc. announced underwritten public offering. Biomerica is offering an aggregate of 3,333,333 shares of its common stock, par value $0.08 per share, at a price to the public of $2.40 per share.

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the completion of an end of Phase 1 (EOP1) meeting with the US Food and Drug Administration (“US FDA”). SACT-1 is a repurposed small molecule drug formulated in oral suspension targeting neuroblastoma in pediatric patients.

Xtant Medical Holdings, Inc. announced that it will release its financial results for the fourth quarter and full year ended December 31, 2022, before the open of the financial markets on Tuesday, March 7, 2023.

Hansa Biopharma announced that Matthew Shaulis will join the company effective 16 March as Chief Commercial Officer and President of the U.S. affiliate, Hansa Biopharma, Inc.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announces that the Company’s Board of Directors has approved a second-quarter 2023 dividend of $0.19 per share.

Vektor Medical will present complex case studies that expand vMap’s utility at the Annual American College of Cardiology Scientific Session held March 4-6, 2023 in New Orleans.